LivaNova (NASDAQ:LIVN) Posts Earnings Results, Beats Estimates By $0.17 EPS

LivaNova (NASDAQ:LIVN) posted its quarterly earnings results on Wednesday. The company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17, FiscalAI reports. The firm had revenue of $393.10 million during the quarter, compared to analyst estimates of $381.13 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period last year, the company earned $1.11 earnings per share.

Here are the key takeaways from LivaNova’s conference call:

• Broad-based growth led to higher guidance. Third-quarter revenue rose 10% to $393 million, and LivaNova raised its 2026 revenue growth outlook to 9%–10% and adjusted EPS outlook to $4.40–$4.50.
• Cardiopulmonary growth and capacity expansion are supporting further gains. Segment revenue increased 11%, with strength in heart-lung machines and consumables; a new oxygenator line is operational, and the company expects double-digit output growth in 2027.
• Epilepsy momentum strengthened. Revenue grew 11%, supported by higher volume and realized pricing, clinical evidence, and improved reimbursement; LivaNova raised its 2026 epilepsy growth outlook to 8%–9%.
• OSA remains a key future growth opportunity, though commercialization is still ahead. The company cited differentiated clinical results and new category CPT codes expected to take effect in 2028, while planning a limited launch in 2027 and larger commercial investment beginning in 2028.
• Investment and working-capital needs weighed on cash generation. Quarterly adjusted free cash flow fell to $56 million from $62 million a year earlier, while capital spending increased; full-year adjusted free cash flow guidance was maintained at $140 million–$160 million.

LivaNova Price Performance

Shares of LivaNova stock traded up $16.28 during trading on Wednesday, hitting $96.18. The stock had a trading volume of 2,571,488 shares, compared to its average volume of 738,652. The firm has a market cap of $5.30 billion, a price-to-earnings ratio of 28.52 and a beta of 0.91. LivaNova has a 12 month low of $48.82 and a 12 month high of $99.38. The business’s 50-day moving average is $78.56 and its 200 day moving average is $73.10. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the sale, the director owned 4,434 shares of the company’s stock, valued at approximately $345,896.34. This trade represents a 44.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 7,450 shares of company stock valued at $591,839 in the last three months. 0.35% of the stock is owned by corporate insiders.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Quarterly results beat expectations: LivaNova reported adjusted earnings of $1.23 per share, above estimates of $1.03–$1.06 and up from $1.11 a year earlier. Revenue rose 9.9% year over year to $393.1 million, exceeding analyst forecasts of about $381 million. LivaNova Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Full-year outlook improved: The company raised its full-year EPS guidance, signaling increased confidence in its earnings outlook. LivaNova Beats Q3 Estimates and Raises Full-Year EPS Guidance
• Positive Sentiment: Analyst sees more upside: Needham raised its price target to $112 from $93 and maintained a Buy rating, reflecting a more favorable view of the shares. Needham & Company recommendations

Wall Street Analyst Weigh In

A number of analysts recently issued reports on LIVN shares. Weiss Ratings raised LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, October 27th. Stifel Nicolaus set a $85.00 target price on LivaNova in a report on Wednesday, August 5th. Needham & Company LLC upped their price target on LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays raised shares of LivaNova to a “strong-buy” rating in a report on Wednesday, October 7th. Finally, Zacks Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and an average target price of $90.12.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.